A structure-guided platform, in numbers
How our discovery platform turns a crystal structure into a development candidate in 24 months, and what those steps look like today.
News
What we publish, when we publish it.
Company news, science updates, and investor announcements. Filter by category.
Category
BPC-101 Phase 2 enrollment begins
The BPC-101 Phase 2 program is now enrolling patients with HR+/HER2- metastatic breast cancer after prior CDK4/6 inhibition.
How we structure early-stage partnerships
Three partnership models we use with pharma collaborators, and what each one is good for.
Why we built a TL1A program
TL1A sits at the intersection of inflammation and fibrosis. That intersection is where durable inflammatory bowel disease therapies have to act.
We are hiring across research and clinical operations
Open roles across discovery, translational, and clinical operations, with a note on how we interview.
Investor relations, in plain terms
What we publish, when we publish it, and where to find it.